Last reviewed · How we verify
Vaccine Support Cp (Vaccine administration)
The drug, a vaccine, is marketed by Women and Infants Hospital of Rhode Island. It is used to prevent COVID-19, Influenza, Human Papillomavirus, Hepatitis A, and Hepatitis B. The vaccine has undergone 100 trials and has been the subject of 3173 publications. It has generated $21.2B in revenue. The mechanism of action is not specified on Wikipedia. The drug's key indications and clinical differentiation are its ability to prevent multiple diseases. Its commercial significance is its high revenue and widespread use. There are no pipeline developments mentioned.
At a glance
| Generic name | Vaccine administration |
|---|---|
| Sponsor | Women and Infants Hospital of Rhode Island |
| Drug class | vaccine |
| Target | unknown |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19
- Influenza
- Human Papillomavirus
- Hepatitis A
- Hepatitis B
- Meningococcal
- Pneumococcal
- Rotavirus
- Varicella
- Measles, Mumps, and Rubella
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Ibuprofen
- Acetaminophen
- Corticosteroids
- Immunosuppressants
- Live attenuated vaccines
- Interferons
- Thalidomide
- Azathioprine
Key clinical trials
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Testing the SurVaxM Vaccine for Lung Cancer Prevention (PHASE2)
- IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine Support Cp CI brief — competitive landscape report
- Vaccine Support Cp updates RSS · CI watch RSS
- Women and Infants Hospital of Rhode Island portfolio CI